Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins
Stocks in this Quantisnow insightHealth Care
Quantisnow market dataNASDAQ
AKRO
Akero Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2019
Get push alerts for AKRO
Full AKRO profile on Quantisnow Follow AKRO and get a push notification the moment its next story breaks.